Loading...
Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
OBJECTIVE. To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS. Postme...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AlphaMed Press
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227947/ https://ncbi.nlm.nih.gov/pubmed/20156908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0240 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|